Functional muscle ischemia in Duchenne and Becker muscular dystrophy

Research output: Contribution to journalShort surveypeer-review

61 Scopus citations


Duchenne and Becker muscular dystrophy (DMD/BMD) comprise a spectrum of devastating X-linked muscle wasting disease for which there is no treatment. DMD/BMD is caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that stabilizes the muscle membrane and also targets other proteins to the sarcolemma. Among these is the muscle-specific isoform of neuronal nitric oxide synthase (nNOSμ) which binds spectrin-like repeats within dystrophin's rod domain and the adaptor protein a-syntrophin. Dystrophin deficiency causes loss of sarcolemmal nNOS μ and reduces paracrine signaling of muscle-derived nitric oxide (NO) to the microvasculature, which renders the diseased muscle fibers susceptible to functional muscle ischemia during exercise. Repeated bouts of functional ischemia superimposed on muscle fibers already weakened by dystrophin deficiency result in use-dependent focal muscle injury. Genetic and pharmacologic strategies to boost nNOSμ-NO signaling in dystrophic muscle alleviate functional muscle ischemia and show promise as novel therapeutic interventions for the treatment of DMD/BMD.

Original languageEnglish (US)
Article numberArticle 381
JournalFrontiers in Physiology
Volume4 DEC
StatePublished - 2013

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)


Dive into the research topics of 'Functional muscle ischemia in Duchenne and Becker muscular dystrophy'. Together they form a unique fingerprint.

Cite this